Landscapes / Companies
Advenchen Laboratories, LLC not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 3 in all
Trials
3 active
4 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved in China | Dec 2027Phase 3 trial completes | |||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Alveolar Soft Part Sarcoma, Leiomyosarcoma and 6 more | ||||
| Open drug page | |||||
— |
Advenchen Laboratories Nanjing |
Phase 1/2 | 7 Nov 2029Phase 1/2 trial completes | ||
| Next date | 7 Nov 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Solid Tumor | ||||
| Open drug page | |||||
About
- No active trial
- Pegylated Liposomal Doxorubicin
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021